Presentation (CTI)

OBJECTIVES: Following the implementation of the EU HTA Regulation (HTAR), there is a need to monitor how national HTA authorities and bodies (HTAb) provide information that allows developers and patients to better understand their processes. This study evaluates the extent to which HTAb make information on their HTA processes publicly accessible, establishing a baseline against which subsequent changes can be assessed as JCA is adopted at national level.
METHODS: This analysis includes the 34 members of the Joint Clinical Assessments (JCA) subgroup for medicinal products. Data were collected up to April 2026 from public official sources regarding the publication of HTA assessment reports, the disclosure of procedural milestones and the availability of detailed decision rationales. HTAb were contacted to validate the data.
RESULTS: The degree of publicly accessible information differed across the 34 HTAb. For 19/34 (56%) HTAb, at least one defined information element was identified. Among these 19 HTAb, 18 publish their HTA reports and procedural milestone data, while detailed rationale for the recommendation or decision was identified for only 15. Of the procedural milestones evaluated, the HTA submission date is published by 12 HTAb, the recommendation date by 18, and the outcome (HTA recommendation) by 17. For the remaining 15 HTAb, no elements were identified, it remains unclear whether this reflects a lack of disclosure or whether these HTAb, despite belonging to the JCA subgroup, do not currently produce HTA reports.
CONCLUSIONS: Overall, information on HTA activities is publicly available for just over half of the 34 HTAb reviewed. These results suggest a need for more transparent public reporting practices across national HTAb. This baseline will be useful to monitor subsequent changes in the public availability of national HTA information as HTAR implementation progresses.